title: Feasibility of intraperitoneal Trastuzumab treatment in a patient with peritoneal carcinomatosis from gastric cancer.
abstract: OBJECTIVE
  This case report evaluates the feasibility and efficacy of intraperitoneal (IP) trastuzumab administration in gastric cancer (GC) patients with peritoneal carcinomatoses.
  
  
  METHODS
  Peritoneal metastasis is a common sign of advanced tumor stage, tumor progression or disease recurrence in patients with GC. Recently, the role of HER2 overexpression in GC, occurring in about 20% of cases, is correlated with a worse prognosis. We report the case of 61-years old female, admitted to our Hospital after curative surgery for GC with over-expression of HER2. Seven months after the start of first line chemotherapy treatment a pleuro-peritoneal disease progression occurred, documented by cytological exam; according to HER2 status, we decided to treat the patient with IP trastuzumab administration.
  
  
  RESULTS
  Between September and October 2012, the patient (ECOG performance status was 0), underwent to 6 cycles of IP trastuzumab. Trastuzumab was administered weekly at a dose of 150 mg for each cycle after paracentesis. The safety was good, no local complications (e.g. abdominal pain, peritonitis) occurred. The clinical revaluation evidenced a stable peritoneal disease.
  
  
  CONCLUSIONS
  To our knowledge this is the first report on Trastuzumab use to treat IP metastases from GC, with acceptable toxicity and local disease control.
authors.affiliation: Department of Medical Oncology, National Cancer Institute, Aviano, Italy. mberretta@cro.it.
authors.forename: M
authors.initials: M
authors.lastname: Berretta
authors.forename: R
authors.initials: R
authors.lastname: Fisichella
authors.forename: E
authors.initials: E
authors.lastname: Borsatti
authors.forename: A
authors.initials: A
authors.lastname: Lleshi
authors.forename: S
authors.initials: S
authors.lastname: Ioffredo
authors.forename: N
authors.initials: N
authors.lastname: Meneguzzo
authors.forename: V
authors.initials: V
authors.lastname: Canzonieri
authors.forename: A
authors.initials: A
authors.lastname: Di Grazia
authors.forename: R
authors.initials: R
authors.lastname: Cannizzaro
authors.forename: U
authors.initials: U
authors.lastname: Tirelli
authors.forename: S
authors.initials: S
authors.lastname: Berretta
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002277:Carcinoma; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D010534:Peritoneal Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary*; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D000068878:Trastuzumab / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000068878:Trastuzumab